Prof. Dr. Thierry VANDENDRIESSCHE

www.thierryvandendriessche.com

A. Current positions

1) **Full Professor** - Faculty of Medicine – Free University of Brussels (VUB), Belgium www.vub.be
2) **Director - Department of Gene Therapy & Regenerative Medicine – VUB**
http://emge.vub.ac.be/GTRM.php
3) **Full Professor** - Faculty of Medicine - University of Leuven (KUL), Belgium www.kuleuven.be

B. Education

1983-1987:	M.Sc. Biology, Free University of Brussels (VUB); **maxima cum laude**
1989-1991:	M.Sc. Molecular Biology & Biotechnology (VUB); **maxima cum laude**
1987-1992:	Ph.D., Free University of Brussels (VUB); **maxima cum laude**

C. Positions and employment

1992-1993	Postdoctoral fellow National Institutes of Health (NIH) NHLBI (Lab chief: Dr. W. French Anderson), USA.
1993-1995	Postdoctoral fellow NIH, USA, NCHGR (Lab chief: Dr. R. Blaese)
1995-2010	Group leader Vesalius Research Center, VIB, Leuven, Belgium.
1997-2003	Assistant Professor - Faculty of Medicine - University of Leuven, Belgium
2001	Visiting Senior Scientist – NIH, USA (Lab chief: Dr. M. Nirenberg)
2003-2010	Associate Professor – University of Leuven (Belgium), Coordinator PhD school,
2003-2006	Guest Professor -Faculty of Sciences – Free University of Brussels (Belgium)
2005-2010	Guest Professor, Faculty of Medicine - Free University of Brussels (Belgium)
2007-2010	Assistant Professor -Faculty of Sciences – Free University of Brussels (Belgium)
2010-current	Full Professor- Faculty of Medicine - Free University of Brussels (Belgium)
2010-current	Full Professor – Faculty of Medicine - University of Leuven (Belgium)

D. Leadership in the field: Committee & Editorial Board memberships

1) Member of the Editorial Board (Mol. Ther., Gene Ther., Curr. Gene Therapy, J. Gene Med., Hum. Gene Ther.), Editor Hum. Gene Ther. Methods, Methods Editor - Hum. Gene Ther.
2) **President** European Society of Gene and Cell Therapy (www.esgct.eu) (2008-2010), Treasurer (2005-2008); Vice-President (2006-2008); currently: *ex officio* ESGCT board member
3) Committee Member of Advanced Therapies (CAT) - European Medicines Agency (EMA)
4) Commission Chair Gene and Cell Therapy (AFM); Member Study Section NIH grants (Programs of Excellence in Gene Therapy), Member Review Committee Translational Gene Therapy Grants (NL, FR) and Gene Therapy Advisory Committee (UK); reviewer European Research Council (ERC) Starting Grants, Scientific Advisory Board member/advisor biotech companies (e.g. Sanofi-Aventis, Cellectis, Bayer, Genethon, Beacle, etc.)
5) Committee Member of World Federation of Hemophilia, Chair ASGCT & ESGCT Committees
6) Supervised about 20 PhD students, some have now academic positions or went abroad (Harvard, US)

E. Awards

1989	First Prize National University Competition
1995	Second Prize International Competition European Working Group on Gene Therapy
1999	Pharmacia & Upjohn Award for innovative medical research (€25000)
1999	Young Investigator Award International Society for Thrombosis and Hemostasis
1999	Young Investigator Award of the European Society of Gene Therapy
2002	International Johann Lucas Schönlein Award (€5000) for Thrombosis & Hemostasis
2006	Sanofi-Aventis Prize Thrombosis, Hemostasis & Vascular Biology (€12500)

2007	Scientific Prize Belgian Royal Academy of Medicine (Secq-Houssiau Award - €5000)
2007 & 2011	Bayer Schering Hemophilia Special Project Award
2009	Excellence in Research American Society in Gene & Cell Therapy (PhD student/I.Petrus)
2009	**Molecule of the Year Award** – (http://en.wikipedia.org/wiki/ Breakthrough_of_the_Year): prestigious world-wide selection by ISMCBBPR
2011	**Top Scientific Prize - Royal Academy of Medicine (M. Verstraete Award €14000)**
2012	Top abstract selection (out of nearly 2000 participants)- American Society in Gene & Cell Therapy

F. Selected publications (1999-2012) more than 100 publications & about 3000 citations - **only selected papers with IF >10 are shown + >100 invited or selected presentations at international conferences**

1) VandenDriessche et al.	**PNAS**, 18 (96): 10379-10384 (1999).	(IF = 10.8)
2) Carmeliet et al.	**Nat Med.** 7(5): 575-83 (2001).	(IF = 27.9)
3) VandenDriessche, et al.	**Blood** 100(3): 813-822 (2002).	(IF = 10.1)
4) Chuah et al.	**Blood** 101(5):1734-1743 (2003).	(IF = 10.1)
5) Yamada et al.	**Nat. Biotech.** 21(8):885-890 (2003).	(IF = 29.5)
6) De Meyer et al.	**Blood** 107(12):4728-36 (2006).	(IF = 10.4)
7) Aragones et al.	**Nat. Genet.,** 40(2):170-80 (2008).	(IF = 34.3)
8) Mates et al.	**Nat. Genet.,** 1(6):753-61 (2009).	(IF = 34.3)
9) Bossuyt et al.	**Plos. Biol.**7(2):e39 (2009).	(IF = 12.9)
10) Matsui et al.	**Blood**, 114(3):677-85 (2009).	(IF = 10.6)
11) Swinnen et al.	**Circulation**, 120(16):1585-97 (2009).	(IF = 10.9)
12) VandenDriessche et al.	**Blood**, 114(8):1461-8 (2009).	(IF = 10.6)
13) Schneider et al.	**Nat. Rev. Drug Disc.,** 9(3): 195-201 (2010).	(IF = 29.1)
14) Dubois et al.	**J. Am. Coll. Cardiol.** 55(20):2232-43 (2010).	(IF = 12.5)
15) Ward et al.,.	**Blood**, 117(3):798-807 (2010).	(IF = 10.6)
16) Schneider et al.,	**Lancet**, 376:514 (2010).	(IF = 30.8)
17) Mátrai et al.	**Hepatology**, 53(5):1696-707 (2011).	(IF = 10.9)
18) Di Matteo et al.	**Meth. Mol. Biol.** 859:241-54 (2012).	(IF = 13.9)

G. Previous research grants and financial support: (amounting to a total of 8M€ in last 5 years).

(1) Flanders Fund Scientific Research (FWO) N°G.0110.00: Development of in vivo gene therapy for hemophilia A (2000-2005: €161,000); (2) FWO N°G.0254.01 Development of lentiviral vectors for cardiovascular gene therapy (2001-2002: €55,776); (3) FWO N° G.0341.05 Development of nanoparticle technology for gene therapy and "drug delivery" (2005-2008: €160,000); (4) KU Leuven (GOA): Molecular regulation of blood platelet formation and function in hemostasis. (2003-2008: €280,000); (5) EU FP6 INTHER: Development and application of transposons and site-specific integration technologies as non-viral gene delivery methods for ex vivo gene-based therapies (2005-2008: €293,886); (6) EHA: Hematopoietic stem cell based gene therapy for hereditary thrombocytopenia due to GATA-1 deficiency (2005-2006: €65,000); (7) Katharine Dormandy Trust (UK) (2005 & 2006: €113,000); (8) Johnson & Johnson: A lentiviral RNAi screen to identify tyrosine kinase genes required for the proliferation or survival of cancer (2006- 2007: €125,000); (9) Actogenix (IWT): Novel concept for oral delivery of biopharmaceuticals (2007-2008: €300,000); (10) VIB: Flanders Research Grant; 1995-2009 (structural financing: ~ €400,000/yr); (11) Bayer Hemophilia Special Project Award: Induction of immune tolerance against clotting factors by RNAi (2007-2009: $200,000); (12) FWO N° G.0631.07 Gene therapy for hemophilia using improved AAV (2007-2010: €140,000); (13) FWO N° G.0632.07 Development of novel site-specific integrating vectors to minimize the risk of insertional oncogenesis (2007-2010: €120,000); (14) AFM: Cardiac gene delivery for DMD using AAV9 (2007-2008: €82,000); (15) EU FP6: CliniGene: Transposon-based gene therapies (2010-11: €50,000); (16) Johnson & Johnson: Novel platforms and complex cell models for the identification of innovative drug targets (2010-2011: €480,000).

H. Current research grants: nearly 4M€

(1) EU FP7: PERSIST Persisting transgenes (2009-2012: €942,040); (2) Cellectis: Meganuclease-mediated gene transfer (2009-2012: €596,581); (3) Role of microRNA in hepatocarcinogenesis (2009-2013): €280,000 (Cancer Foundation), €169,600 (FWO); (4) VUB (GOA): Interplay between epigenetic modification mechanisms and miRNA (2011-2015: €309750); (5) Hepatic gene therapy for hemophilia using integration-defective lentiviral vectors (2011-2015): €150,000 (AFM), €72,000 (EHA), €140,000 (FWO); (6) AFM: Non-viral stem cell-based gene therapy for DMD using novel hyperactive transposons (2009- 2011: 65,000 €); (7) Generation of DM1-specific induced iPS: 120,000€ (King Boudewijn Foundation) (2011-2013), 120,000€ (FWO) (2012-2015) & 140,000€ (AFM) (2012-2013); (8) Gene therapy of hemophilia 'A'. Bayer-Schering Hemophilia Special Project Award: 150,000€ (2011-2012); 93,000€ (FWO) (2012-2015).